TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39466427

Group type: EXPERIMENTAL
Intervention: Hugo™ Robotic-Assisted Surgery System
Number of subjects: 20
Study: 39466542

Group type: EXPERIMENTAL
Intervention: Deep learning (DL)-based reconstruction
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional reconstruction
Number of subjects: 50
Study: 39466584

Group type: EXPERIMENTAL
Intervention: Augmenting adaptations
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Reducing/Reordering adaptations
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Therapist-reported adaptations
Number of subjects: 70
Study: 39466640

Group type: EXPERIMENTAL
Intervention: Early valve intervention (transcatheter or surgical aortic valve replacement)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Guideline-directed conservative management
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Early valve intervention
Number of subjects: 224
Study: 39466816

Group type: EXPERIMENTAL
Intervention: Azithromycin (single dose)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 39466830

Group type: EXPERIMENTAL
Intervention: AI-DP (KK2.0)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual screening of KK stool thick smears (KK1.0)
Number of subjects: 0
Study: 39466903

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 901

Group type: COMPARATOR
Intervention: Clinical Surveillance
Number of subjects: 901
Study: 39466933

Group type: EXPERIMENTAL
Intervention: KSL-W chewing gum (30 mg dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KSL-W chewing gum (doses ≥ 20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KSL-W chewing gum (2-100 mg single doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KSL-W chewing gum (4-75 mg multiple doses)
Number of subjects: 0
Study: 39467244

Group type: EXPERIMENTAL
Intervention: goflkicept therapy
Number of subjects: 16
Study: 39467285

Group type: EXPERIMENTAL
Intervention: Early in-bed cycle ergometry
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 360
Study: 39467288

Group type: EXPERIMENTAL
Intervention: VR-based social skills training
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Traditional social skills training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 90
Study: 39467538

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 44
Study: 39467550

Group type: EXPERIMENTAL
Intervention: Connected health devices combined with statistical process control (CUSUM) for monitoring respiratory function.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Patient education associated with the intervention.
Number of subjects: 36
Study: 39467591

Group type: EXPERIMENTAL
Intervention: PACK training (intervention)
Number of subjects: 48
Study: 39467616

Group type: EXPERIMENTAL
Intervention: Residual depressive symptoms
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Baseline depression severity
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Being in a relationship
Number of subjects: 1244
Study: 39467833

Group type: EXPERIMENTAL
Intervention: Local skin cooling for five seconds during arteriovenous fistula cannulation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard hospital protocol (control group)
Number of subjects: 50
Study: 39467892

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) treatment of sockets after third molar removal
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional treatment of sockets after third molar removal
Number of subjects: 25
Study: 39468229

Group type: COMPARATOR
Intervention: Urea cycle amino acids (ornithine, citrulline, homocitrulline, aspartate, arginine)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Lysine, histidine, and the glutamine/glutamate ratio
Number of subjects: 166
Study: 39468444

Group type: EXPERIMENTAL
Intervention: Post-Stroke Checklist (PSC) follow-up at 3 and 12 months post-stroke
Number of subjects: 200
Study: 39468466

Group type: EXPERIMENTAL
Intervention: U. parvum serovar 14
Number of subjects: 5277

Group type: EXPERIMENTAL
Intervention: U. parvum serovar 3
Number of subjects: 5277

Group type: COMPARATOR
Intervention: U. parvum serovar 1
Number of subjects: 5277

Group type: COMPARATOR
Intervention: U. parvum serovar 6
Number of subjects: 5277
Study: 39468472

Group type: EXPERIMENTAL
Intervention: Prenatal prevention consultation offered to future fathers
Number of subjects: 2516

Group type: EXPERIMENTAL
Intervention: Prenatal prevention consultation
Number of subjects: 2516
Study: 39468538

Group type: EXPERIMENTAL
Intervention: Osseodensification sinus lift using sticky bone as a graft material
Number of subjects: 16

Group type: COMPARATOR
Intervention: Piezoelectric internal sinus elevation (PISE) using sticky bone as a graft material
Number of subjects: 16
Study: 39468582

Group type: EXPERIMENTAL
Intervention: Trach Plus
Number of subjects: 6

Group type: COMPARATOR
Intervention: Trach Me Home (Comparator)
Number of subjects: 6
Study: 39468592

Group type: EXPERIMENTAL
Intervention: Ravulizumab treatment
Number of subjects: 56
Study: 39468623

Group type: EXPERIMENTAL
Intervention: Functional hip abductor strength training combined with traditional physical therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional physical therapy
Number of subjects: 40
Study: 39468632

Group type: EXPERIMENTAL
Intervention: Cast immobilization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Operative treatment followed by cast immobilization
Number of subjects: 0
Study: 39468643

Group type: EXPERIMENTAL
Intervention: Green coffee (GC) capsules (800 mg) daily for 6 months
Number of subjects: 160
Study: 39468649

Group type: EXPERIMENTAL
Intervention: Multimodal, digitally enhanced intervention including a smartwatch, study app, mobile integrated health program, and virtual pulmonary support service.
Number of subjects: 100
Study: 39468701

Group type: EXPERIMENTAL
Intervention: Tucidinostat plus pediatric-inspired chemotherapy
Number of subjects: 54
Study: 39468861

Group type: EXPERIMENTAL
Intervention: Delirium-weakness group
Number of subjects: 247

Group type: COMPARATOR
Intervention: Delirium-only group
Number of subjects: 247

Group type: COMPARATOR
Intervention: Weakness-only group
Number of subjects: 247

Group type: COMPARATOR
Intervention: Normal group
Number of subjects: 247
Study: 39469237

Group type: EXPERIMENTAL
Intervention: Women with endometriosis
Number of subjects: 381

Group type: COMPARATOR
Intervention: Control women
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Partners of women with endometriosis
Number of subjects: 381

Group type: COMPARATOR
Intervention: Partners of control women
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Chronic pain, dyspareunia, dissatisfaction with sexuality, fatigue, and infertility
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Fatigue and infertility
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Male partners in both groups
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: High intensity of pain experienced by partner
Number of subjects: 381
Study: 39469294

Group type: EXPERIMENTAL
Intervention: Virtually delivered mind-body program integrating tai chi, qigong, and meditation (VDTQM), 12-week program, live online 60-minute classes twice weekly.
Number of subjects: 350

Group type: COMPARATOR
Intervention: Waitlist control group, n=175.
Number of subjects: 350
Study: 39469536

Group type: EXPERIMENTAL
Intervention: CVN424 50 mg
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: CVN424 150 mg
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 39469537

Group type: EXPERIMENTAL
Intervention: Dietary inorganic nitrate (70 mL of nitrate-containing beetroot juice) for 6 months
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (nitrate-deplete juice) for 6 months
Number of subjects: 300
Study: 39469641

Group type: EXPERIMENTAL
Intervention: Triple combination of vemurafenib (vem), cobimetinib (cobi), and atezolizumab (atezo)
Number of subjects: 59
Study: 39469838

Group type: EXPERIMENTAL
Intervention: Dato-DXd + pembrolizumab + platinum-based chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dato-DXd + pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: pembrolizumab + pemetrexed + platinum chemotherapy
Number of subjects: 0
Study: 39470043

Group type: EXPERIMENTAL
Intervention: 0h/1h hs-cTnT protocol
Number of subjects: 26040

Group type: COMPARATOR
Intervention: 0h/3h hs-cTnT protocol
Number of subjects: 26040
Study: 39470045

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) performed during the first 24 hours after angiography
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: LUS score as an independent predictor
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Detecting B-lines on LUS
Number of subjects: 373
Study: 39470058

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 668
Study: 39470180

Group type: EXPERIMENTAL
Intervention: YBCS's perceived cancer risk
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Older relatives' physical QOL at baseline
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Demographic, clinical, and psychosocial factors (age, race, marital status, years since diagnosis, education, out-of-pocket costs of care, routine sources of care, income, family support, fear of recurrence, anxiety, and depression)
Number of subjects: 310
Study: 39470206

Group type: COMPARATOR
Intervention: Conservative interventions (assessment-based nursing, holistic nursing, probiotics, psyllium, faecal microbiota transplantation, stepwise protocol of increasingly invasive evacuation methods)
Number of subjects: 1598

Group type: COMPARATOR
Intervention: Conservative interventions
Number of subjects: 1598

Group type: COMPARATOR
Intervention: Physical therapies (massage therapy, standing, osteopathic manipulative treatment, electrical stimulation, transanal irrigation, conventional physical therapy with visceral mobilisation)
Number of subjects: 1598

Group type: COMPARATOR
Intervention: Physical therapies
Number of subjects: 1598

Group type: COMPARATOR
Intervention: Surgical interventions
Number of subjects: 1598
Study: 39470284

Group type: EXPERIMENTAL
Intervention: Point-of-care nucleic acid device using caregiver/patient self-collected buccal swabs
Number of subjects: 2640

Group type: COMPARATOR
Intervention: Reference standard: nasopharyngeal swab specimens collected by a healthcare provider tested via laboratory RT-PCR
Number of subjects: 2640
Study: 39470337

Group type: EXPERIMENTAL
Intervention: Right Bundle Branch Block (RBBB)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Left Bundle Branch Block (LBBB)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: No Bundle Branch Block (No BBB)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: RBBB
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: LBBB
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: No BBB
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Lactate
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Troponin I
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Acute Physiology Score
Number of subjects: 248
Study: 39470416

Group type: EXPERIMENTAL
Intervention: Diaphragmatic motion assessment in patients with pneumonia
Number of subjects: 39

Group type: COMPARATOR
Intervention: Diaphragmatic motion assessment in patients with exacerbation of chronic obstructive pulmonary disease
Number of subjects: 39

Group type: COMPARATOR
Intervention: Diaphragmatic motion assessment in patients with acute heart failure
Number of subjects: 39
Study: 39470511

Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block (QLB)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 39470554

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) + medical treatment + stabilization splint
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (medical treatment + stabilization splint)
Number of subjects: 61
Study: 39470695

Group type: EXPERIMENTAL
Intervention: Digital care program (DCP) with race/ethnicity concordance
Number of subjects: 71201

Group type: EXPERIMENTAL
Intervention: Digital care program (DCP) with gender concordance
Number of subjects: 71201
Study: 39470705

Group type: EXPERIMENTAL
Intervention: eHealth PA intervention (n=50)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Usual care (n=49)
Number of subjects: 99
Study: 39470716

Group type: EXPERIMENTAL
Intervention: Happy Hands app-based self-management intervention
Number of subjects: 71
Study: 39470752

Group type: EXPERIMENTAL
Intervention: Atrial strain measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aortic stiffness measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hand grip strength assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knee extensor strength assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Muscle oxygenation recording
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0
Study: 39470786

Group type: EXPERIMENTAL
Intervention: Holmium-166 radioembolisation
Number of subjects: 31
Study: 39470788

Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy for adolescents (DBT-A)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: DBT-A
Number of subjects: 77
Study: 39470875

Group type: EXPERIMENTAL
Intervention: Non-ablative diode laser therapy
Number of subjects: 22
Study: 39470878

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39470977

Group type: EXPERIMENTAL
Intervention: Culturally adapted recruitment strategies (including revised language and imagery, targeted outreach, and incorporation of treating physicians) implemented post-May 17, 2022.
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Culturally adapted recruitment strategies
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Changes in recruitment letter
Number of subjects: 385
Study: 39471078

Group type: EXPERIMENTAL
Intervention: CART identified lower IL9, lower presentation pulse rate, and higher eotaxin as predictors of vasospasm development.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: LASSO identified higher Rotterdam computed tomography score and lower age as risk factors for vasospasm development.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: CART identified high levels of eotaxin as most predictive of mortality.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: LASSO identified higher serum IL6, lower IL12, and higher glucose as predictive of mortality.
Number of subjects: 53
Study: 39471088

Group type: EXPERIMENTAL
Intervention: Neuro-Spinal Scaffold (NSS) implantation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Spine surgery alone (control group)
Number of subjects: 20
Study: 39471309

Group type: EXPERIMENTAL
Intervention: TAVR with Sentinel cerebral embolic protection (CEP) device
Number of subjects: 3000

Group type: COMPARATOR
Intervention: TAVR alone
Number of subjects: 3000
Study: 39471424

Group type: EXPERIMENTAL
Intervention: Selpercatinib 20 mg QD or 20-240 mg BID in phase I; 160 mg BID in phase II.
Number of subjects: 837
Study: 39471440

Group type: EXPERIMENTAL
Intervention: Donor Arm
Number of subjects: 113

Group type: COMPARATOR
Intervention: No Donor Arm
Number of subjects: 113
Study: 39471473

Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 386

Group type: COMPARATOR
Intervention: CO2 Insufflation (Control)
Number of subjects: 386
Study: 39471475

Group type: EXPERIMENTAL
Intervention: Umbilical cord blood transplantation (UCBT) with standard-of-care myeloablative conditioning; 4 subjects also received intrathecal DUOC-01 cells posttransplant.
Number of subjects: 8
Study: 39471820

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIC) twice daily for 2-4 days before carotid artery stenting (CAS) as an adjunct to standard medical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIC)
Number of subjects: 0
Study: 39472058

Group type: EXPERIMENTAL
Intervention: Hydrocortisone replacement (20 mg/day for 3 months, then 10 mg/day for 3 months)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Prednisone tapering (1 mg/day every month until complete discontinuation)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Hydrocortisone replacement
Number of subjects: 102

Group type: COMPARATOR
Intervention: Prednisone tapering
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study: 39472200

Group type: EXPERIMENTAL
Intervention: Extended pelvic lymph node dissection (PLND) including external iliac, obturator, and hypogastric nodes
Number of subjects: 1432

Group type: COMPARATOR
Intervention: Limited pelvic lymph node dissection (PLND) including external iliac nodes
Number of subjects: 1432
Study: 39472354

Group type: EXPERIMENTAL
Intervention: uPAR-PET tracer administration (approximately 200 MBq, range: 83-222 MBq)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: uPAR expression as a continuous variable
Number of subjects: 24
Study: 39472409

Group type: EXPERIMENTAL
Intervention: Heated Tobacco Products (HTPs) inhalation
Number of subjects: 23
Study: 39472511

Group type: EXPERIMENTAL
Intervention: Intrauterine infusion of autologous platelet-rich plasma (PRP) 0.8-1 ml 48 hours before blastocyst ET in fresh and frozen cycles
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intrauterine infusion of autologous platelet-rich plasma (PRP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no PRP infusion)
Number of subjects: 80
Study: 39472768

Group type: EXPERIMENTAL
Intervention: PRX004 (0.1, 0.3, 1, 3, 10 or 30 mg/kg), administered intravenously every 28 days for 3 months
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: PRX004 (≥3 mg/kg for ≥9 months)
Number of subjects: 21
Study: 39472831

Group type: EXPERIMENTAL
Intervention: Intrauterine misoprostol (400 mg) + oxytocin
Number of subjects: 192

Group type: COMPARATOR
Intervention: Sublingual misoprostol (400 mg) + oxytocin
Number of subjects: 192
Study: 39472953

Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty (Wolverine™)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Non-compliant balloon
Number of subjects: 250
Study: 39472975

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MCI) including health coaching, physician training, medication subsidy, and case review meetings
Number of subjects: 896

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 896
Study: 39473003

Group type: EXPERIMENTAL
Intervention: 0.2% hyaluronic acid gel-impregnated dental floss
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dental floss alone
Number of subjects: 0
Study: 39473014

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Computed precision doses of tDCS
Number of subjects: 16
Study: 39473017

Group type: EXPERIMENTAL
Intervention: High-risk patients (APACHE II score ≥ 15, invasive pulmonary aspergillosis, therapeutic dose of anticoagulants, extracorporeal membrane oxygenation, continuous renal replacement therapy)
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Blood transfusion not related to bleeding
Number of subjects: 931
Study: 39473051

Group type: EXPERIMENTAL
Intervention: Exercise training for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline gut fungal signatures
Number of subjects: 0
Study: 39473059

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiation therapy and docetaxel (45 Gy radiotherapy in 25 fractions over 5 weeks, weekly dose-escalated docetaxel up to 30 mg/m²)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiation therapy and docetaxel
Number of subjects: 25
Study: 39473076

Group type: EXPERIMENTAL
Intervention: Crizanlizumab (5 mg/kg)
Number of subjects: 112
Study: 39473159

Group type: EXPERIMENTAL
Intervention: High risk individuals (HR)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Recently detoxified alcohol-dependent (AD)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Low risk (LR)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: GABA levels in the ACC
Number of subjects: 96

Group type: COMPARATOR
Intervention: Abstinence duration in AD
Number of subjects: 96
Study: 39473396

Group type: EXPERIMENTAL
Intervention: Vitamin D levels in children with nocturnal enuresis
Number of subjects: 120

Group type: COMPARATOR
Intervention: Vitamin D levels in healthy control children
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Correlation of Vitamin D levels with nocturnal urine osmolality
Number of subjects: 120
Study: 39473503

Group type: EXPERIMENTAL
Intervention: Follicular phase laparoscopic endometrioma surgery
Number of subjects: 55

Group type: COMPARATOR
Intervention: Luteal phase laparoscopic endometrioma surgery
Number of subjects: 55
Study: 39473704

Group type: EXPERIMENTAL
Intervention: Collagen paste injection
Number of subjects: 14
Study: 39474371

Group type: EXPERIMENTAL
Intervention: Asymptomatic carotid artery stenosis (CAS) patients
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Asymptomatic carotid artery stenosis (CAS) patients with SBI
Number of subjects: 195
Study: 39474441

Group type: EXPERIMENTAL
Intervention: EGD in patients aged 61-70 years
Number of subjects: 1003

Group type: COMPARATOR
Intervention: EGD in patients aged 51-60 years
Number of subjects: 1003

Group type: COMPARATOR
Intervention: EGD in patients aged 41-50 years
Number of subjects: 1003
Study: 39474484

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39474711

Group type: EXPERIMENTAL
Intervention: Postoperative lymphopaenia on postoperative day 1 (POD1)
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Surgery duration > 200 minutes
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: ASA score IV
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Changes in postoperative lymphocyte counts (LC) over time
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Preoperative lymphocyte counts (LC)
Number of subjects: 1207
Study: 39474720

Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg/day
Number of subjects: 261

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg/day
Number of subjects: 261
Study: 39474765

Group type: EXPERIMENTAL
Intervention: Distal Radial Access (DRA)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Traditional Radial Access (TRA)
Number of subjects: 850